Comparative Pharmacology
Head-to-head clinical analysis: ALESSE versus STILBETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALESSE versus STILBETIN.
ALESSE vs STILBETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, inhibiting pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby preventing ovulation. Additionally, it thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity.
Diethylstilbestrol (STILBETIN) is a nonsteroidal estrogen that binds to estrogen receptors, activating estrogen-responsive genes, leading to increased synthesis of proteins involved in growth and differentiation of female reproductive tissues.
One tablet (ethinyl estradiol 20 mcg, levonorgestrel 0.1 mg) orally once daily at the same time each day for 21 days, followed by 7 days of placebo. For initiation, start on the first day of menstrual period or first Sunday after onset of menses.
25 mg orally 3 times daily for 5 days; repeat if necessary after 1 month.
None Documented
None Documented
Levonorgestrel: terminal half-life ~17-20 hours (range 11-25 hr). Ethinyl estradiol: biphasic; terminal half-life ~13-27 hours (mean ~17 hr). Clinical context: steady-state achieved within 5-7 days. The half-life supports once-daily dosing with at least 24-hour contraceptive coverage.
Terminal elimination half-life is approximately 1-2 hours (range 1-3 h) for estradiol; clinical relevance: requires multiple daily dosing (e.g., 3-4 times/day) for sustained effect.
Renal: ethinyl estradiol (UE2) and levonorgestrel (LNG) metabolites primarily excreted in urine (UE2: ~40% as sulfate and glucuronide conjugates; LNG: ~25% as glucuronides). Fecal/biliary: ~40% (UE2) and ~45% (LNG) eliminated in feces via bile. Unchanged drug excretion is negligible.
Primarily renal as glucuronide and sulfate conjugates; approximately 50-80% of a parenteral dose excreted in urine within 24 hours; 10-20% via bile into feces.
Category C
Category C
Estrogen/Progestin Combination Contraceptive
Estrogen